Summit Therapeutics Inc.
SMMT
Rangering i aksjer
#1703
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aksjekurs
$15.71
Sist synkronisert: 2026-10-19
Markedsverdi
$12.53B
Endring (1 dag)
7.35%
Endring (1 år)
-21.63%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
EPS for Summit Therapeutics Inc. (SMMT)
EPS per June 2026 TTM: $-1.12
Ifølge de siste økonomiske rapportene og aksjekursen til Summit Therapeutics Inc. er selskapets nåværende EPS (TTM) $-1.12. Ved slutten av 2023 hadde selskapet en EPS på $-0.99, en økning sammenlignet med EPS-en i 2022 som var $-0.41.
EPS-historikk for Summit Therapeutics Inc. fra 2004 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-1.12 | 261.29% |
| 2024 | $-0.31 | -68.69% |
| 2023 | $-0.99 | 141.46% |
| 2022 | $-0.41 | -57.29% |
| 2021 | $-0.96 | 26.32% |
| 2020 | $-0.76 | 282.10% |
| 2019 | $-0.20 | -12.46% |
| 2018 | $-0.23 | -58.03% |
| 2017 | $-0.54 | -7.28% |
| 2016 | $-0.58 | -9.84% |
| 2015 | $-0.65 | 15.87% |
| 2014 | $-0.56 | -16.06% |
| 2013 | $-0.67 | 17.30% |
| 2012 | $-0.57 | 86.96% |
| 2011 | $-0.30 | 45.47% |
| 2010 | $-0.21 | -75.78% |
| 2009 | $-0.86 | 3.18% |
| 2008 | $-0.84 | 166.41% |
| 2007 | $-0.31 | 191.63% |
| 2006 | $-0.11 | 1,435.71% |
| 2005 | $-0.01 | 75.00% |
| 2004 | 0.00 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -1,646.43% |
US
|
|
| $-7.98 | 612.50% |
US
|
|
| $-5.29 | 372.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,576.79% |
NL
|
